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Ohara: Patenting a Diagnosis

NOTE
PATENTING THE DIAGNOSIS OF A
DISEASE: THE SCOPE OF
PATENTABLE SUBJECT MATTER
BASED ON LABCORP V.
METABOLITE LABS
INTRODUCTION: THE STRUGGLE TO DEFINE THE SCOPE OF PATENTABLE
SUBJECT MATTER

Determining the limits of what should be patentable subject matter
is a fundamental issue of patent law. Congress defined patentable
subject matter in 35 U.s.C. § 101 as a "new and useful process, machine,
manufacture, or composition of matter, or any new and useful
improvement thereof."t The United States Supreme Court in Diamond v.
Chakrabarty noted that 35 U.S.c. § 101 should be construed broadly to
promote innovation and account for unforeseeable changes in
technology.2 However, the Court also noted that 35 U.S.c. § 101 cannot
be construed so broadly as to allow patenting of "[t]he laws of nature,
physical phenomena, and abstract ideas.,,3
Currently, a method of diagnosing a disease can be broadly claimed
in a patent. 4 In Metabolite Laboratories, Inc. v. Laboratory Corp. of
America Holdings, the United States Court of Appeals for the Federal

135 V.S.C.A. § 101 (Westlaw 2007).
2 See Diamond v. Chakrabarty, 447 V.S. 303, 316 (1980). The Court construed § 101 to
encompass microorganisms. [d. at 318.
3 [d. at 309.
4 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361-65 (Fed. CiT.
2004).
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Circuit recently upheld the patentability of a method-of-diagnosis claim
for a vitamin B deficiency.5 The method claim correlated an elevated
level of total homocysteine to a vitamin B deficiency.6 This method
claim was not limited to a particular procedure for performing the
measurement. 7 In fact, the method claim was arguably construed to
cover all future improvements to the measurement method so long as the
resulting measurement was used for the determination of a vitamin B
deficiency. 8
The United States Supreme Court initially granted certiorari in
Metabolite Labs to decide whether the method-of-diagnosis claim was
patentable. 9 Later, the Court dismissed certiorari as improvidently
granted. \0 This Note asserts that the Court should have adjudicated the
case because there is a great need to clarify what is patentable subject
matter for method claims that do not entail a physical transformation of
matter, particularly in view of the seeming inconsistency between
Diamond v. Diehr and State Street Bank & Trust Co. v. Signature
Financial Group. I I There is strong public interest in clarifying 35 U.S.C.
§ 101, as evidenced by an unusually large number of amici briefs in
LabCorp.12 Twenty amici briefs were submitted from a diverse group of
entities such as the American Association of Retired People,13 American
Medical Association,14 American Express,15 IBM,16 Bear Stearns &

5 [d.

at 1368.

[d. at 1358-59.
7 See id.

6

S See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of
Petitioner at 13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No.
04-067).
9 Petition for a Writ of Certiorari, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126
S. Ct. 2921 (2006) (No. 04-067), available at 2004 WL 2505526; Lab. Corp. of Am. Holdings v.
Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 543 (2005) (limiting grant of certiorari to issue three
only).
IO Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2922
(2006).
II See id. at 2928 (Breyer, J., dissenting). Compare Diamond v. Diehr, 450 U.S. 175, 192
(1980) (holding that a method claim that includes a physical transformation of matter is patentable)
with State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir. 1998)
(holding that a method claim that produces '''a useful, concrete, and tangible result'" is patentable).
12 LabCorp, 126 S. Ct. at 2926 (Breyer, J., dissenting).
13 Brief Amicus Curiae of AARP in Support of Petitioner, Lab. Corp. of Am. Holdings v.
Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
14 Brief for the American Medical Association, the American College of Medical Genetics,
the American College of Obstetricians and Gynecologists, the Association for Molecular Pathology,
the Association of American Medical Colleges, and the College of American Pathologists as Amici
Curiae in Support of Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct.
2921 (2006) (No. 04-067 ).
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Lehman Brothers, 17 Affymetrix, 18 Perlegen,19 American Clinical
Laboratory Association,20 and the Computer & Communications Industry
Association. 21
This Note additionally asserts that a patent claiming a method of
diagnosing a disease that consists of essentially two steps-(1) a medical
measurement that is not specific to a particular method, and (2) a
correlation step that uses the medical measurement for identifying a
disease state-should not be patentable subject matter under 35 U.S.C. §
22
101. As currently construed by the court of appeals in Metabolite Labs,
a method-of-diagnosis claim can cover all improvements to the
measurement method that will likely be invented in the future. 23 The
method claim in Metabolite Labs essentially grants a monopoly over a
natural phenomenon, and allowing such monopolies will impede
progress in developing improved medical measurements and thus deprive
the public of potential advancements in healthcare. 24
Part I will provide a brief background in patent law, describe the

15 Brief of Amicus Curiae American Express Company in Support of Neither Party, Lab.
Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
16 Brief of International Business Machines Corporation as Amicus Curiae in Support of
Neither Party, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No.
04-067).
17 Brief of Financial Services Industry Amici Curiae in Support of Reversal, 126 S. Ct. 2921
(2006) (No. 04-067).
18 Brief Amicus Curiae of Affymetrix, Inc. and Professor John H. Barton in Support of
Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04067).
19 Brief for Amicus Curiae Per1egen Sciences, Inc. and Mohr, David Ventures in Support of
Respondents, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04067).
20 Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of
Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04067).
21 Brief for Amicus Curiae Computer & Communications Industry Association in Support of
Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04067).
22 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921,
2927 (2006) (Breyer, J., dissenting).
23 See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of
Petitioner at 13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No.
04-067); Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1362-64 (Fed. Cir.
2004). Abbott Laboratories later developed an improved assay that was held to be an infringing
assay. Brief for Respondents at 7, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct.
2921 (2006) (No. 04-067), available at 2006 WL 303905.
24 See Michael Meehan, The Handiwork of Nature:
Patentable Subject Matter and
Laboratory Corporation v. Metabolite Labs, 16 ALB. L.J. SCI. & TECH 311, 317 (2006); see also
Brooks Gifford, Paper, Oh, Diehr: The CAFe'S Troubling Patent Eligibility Jurisprudence as
Applied in Metabolite Laboratories v. LabCorp, 25 BIOTECHNOLOGY L. REP. 129, 129 (2006).
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current interpretation of 35 U.S.C. § 101 for method claims, and
summarize the facts and procedural history of the suit against LabCorp.25
Part II will analyze why the Federal Circuit's interpretation of a method
of diagnosing a vitamin B deficiency was too broad and will inhibit
future research needed for better healthcare. 26 Part III will conclude that
the Supreme Court should have reversed the Federal Circuit's decision in
Metabolite Labs. 27
I.

BACKGROUND

To enhance the discussion of LabCorp, infra, a review of basic
patent law will be provided. Next, the current interpretation of 35 U.S.C.
§ 10 1 for software method claims will be summarized. Issues that the
biotech industry is facing due to the current application of 35 U.S.C. §
101 also will be presented. Finally, the facts regarding the discovery of
the method of diagnosing a vitamin B deficiency and the procedural
history of the infringement suit against LabCorp will be set forth.
A.

PATENT LAW BASICS

Article I, section 8, clause 8, of the United States Constitution gave
Congress the right to regulate patents for promoting "the Progress of
Science and the useful ArtS.,,28 A person who invents a "new and useful
process, machine, manufacture, or composition of matter" may apply for
and obtain a patent. 29 An inventor may apply for a patent by submitting
an application to the United States Patent and Trademark Office
(USPTO).3o If a patent examiner at the USPTO finds that the invention
is novel and non-obvious based on the prior art,3l a patent will be
granted. 32 The inventor will then receive a limited monopoly on his or
her invention for a term beginning on the date on which the patent issues

See infra notes 28-161 and accompanying text.
26 See infra notes 162-312 and accompanying text
27 See infra notes 313-317 and accompanying text.
28 U.S. CONST art. I, § 8, c1. 8.
29 35 U.S.C.A. § 101 (Westlaw 2007).
30 35 U.S.C.A. § III (WestIaw 2007); see also U.S. Patent & Trademark Office, Patent, How
to Get a, http://www.uspto.gov/web/patents!howtopat.htm (last visited Mar. 18, 2007).
31 "Prior art" a body of knowledge from the beginning of time that may include public
knowledge, public use, a patent, a printed publication, or a public sale. See 35 U.S.C. § 102
(WestIaw 2007); Walter J. Blenko, Jr., Considering What Constitutes Prior Art in the United States,
43 JOM 45 (1991), available at http://www.tms.orglpubsljournals/JOM/matterslmatters-9106.html.
32
35 U.S.C.A. §§ 102, 103 (Westlaw 2007).
25
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and ending twenty years from the date the application was filed. 33 In
exchange for the limited monopoly, the invention will be free for the
public to use once the patent expires. 34 Further, the invention will
usually be published eighteen months after filing of the application so
that the public can improve upon the invention or design around the
invention. 35 Thus, patent law must provide '''a careful balance'"
between the benefits to the inventor in the form of a limited monopoly,
and the utility to the public in the form of public disclosure, because the
patent system is the "very lifeblood of a competitive economy.,,36
A patent provides a patentee the right to exclude others from
infringing the patent. 37 There are two types of infringement, direct and
indirect. 38 Direct infringement occurs when one makes, uses, offers to
sell, or sells any patented invention within the United States and without
authority. 39 To directly infringe a patent, the accused infringer must
perform each and every element of a patent claim.40 The intent of the
infringer does not matter when evaluating direct infringement,41 in
contrast to indirect infringement. 42
One form of indirect infringement is inducement to infringe, which

35 U.S.C.A. § 154(a)(2) (Westlaw 2007).
34 See Bonito Boats v. Thunder Craft Boats. 489 U.S. 141.152 (1989).
35 35 U.S.C.A. § 122 (Westlaw 2007).
36 See Brief for Amicus Curiae Affymetrix. Inc. and Professor John H. Barton in Support of
Petitioner at 12. Lab. Corp. of Am. Holdings v. Metabolite Labs .• Inc .• 126 S. Ct. 2921 (2006) (No.
04-067) (citing Bonito Boats. 489 U.S. at (46).
37 "[Wlhoever without authority makes. uses. offers to sell. or sells any patented invention.
within the United States or imports into the United States any patented invention during the term of
the patent therefor. infringes the patent." 35 U.S.c.A. § 271(a) (Westlaw 2007) (direct
infringement). "Whoever actively induces infringement of a patent shall be liable as an infringer."
U.S.C. § 271(b) (Westlaw 2007) (inducement to infringe). "Whoever offers to sell or sells within
the United States or imports into the United States a component of a patented machine. manufacture.
combination or composition. or a material or apparatus for use in practicing a patented process.
constituting a material part of the invention. knowing the same to be especially made or especially
adapted for use in an infringement of such patent. and not a staple article or commodity of commerce
suitable for substantial noninfringing use. shall be liable as a contributory infringer." 35 U.S.C.A..
271(c) (Westlaw 2007) (contributory infringement). A further discussion of 35 U.S.C.A. § 271(c) is
beyond the scope of this Note.
38 35 U.S.C.A. § 271 (a).(b) (Westlaw 2007).
39 35 U.S.C.A. § 271 (a) (Westlaw 2007).
40 Warner-Jenkinson Co .• Inc. v. Hilton Davis Chemical Co .• 520 U.S. 17. 29 (1997); see also
Prouty v. Ruggles. 41 U.S. 336. 341 (1842); Kristin E. Gerdelman. Comment. Subsequent
Performance of Process Steps by Different Entities: Time to Close Another Loophole in U.S. Patent
Law. 53 EMORY LJ. 1987. 1994-95 (2004).
41 Warner-Jenkinson. 520 U.S. at 35.
42 Kristin E. Gerdelman. Comment. Subsequent Performance of Process Steps by Different
Entities: Time to Close Another Loophole in U.S. Patent Law. 53 EMORY LJ. 1987. 1994 (2004)
(citing Water Techs. Corp. v. Calco. Ltd .• 850 F.2d 660. 668 (Fed. Cir. (988».
33

Published by GGU Law Digital Commons, 2007

5

Golden Gate University Law Review, Vol. 38, Iss. 1 [2007], Art. 5

144

GOLDEN GATE UNIVERSITY LAW REVIEW

[Vol. 38

occurs when a party actively induces or encourages infringement by
another party.43 As a threshold consideration, it must be determined
whether someone directly infringed the patent. 44 Next, there must be
evidence that the alleged indirectly infringing party encouraged another
to perform the infringing act. 45 Either direct or circumstantial evidence
may be used for establishing liability for inducement to infringe.46 An
example of circumstantial evidence could be an advertising document
that encourages one to infringe a patent. 47 Lastly, unlike direct
infringement, the party allegedly actively inducing another to infringe
must intend to do SO.48
B.

HISTORY OF UNITED STATES SUPREME COURT DECISIONS
DEFINING PATENTABLE SUBJECT MATIER UNDER 35 U.S.c. §
FOR SOFTWARE-RELATED METHOD CLAIMS

101

Starting around the 1970s, there was an explosion in the
development of computers and software technology that continues to this
day.49 There are "[c]lose to one hundred thousand software or softwarerelated patents [that] are now in force in the United States, and several
thousand more are being issued every year.,,50 In a trio of cases, the
United States Supreme Court defined the patentability requirements for
software-related method5! claims under 35 U.S.c. § 101.52 The most
recent of these decisions for defining patentable subject matter was
decided over 25 years ago. 53 In Diamond v. Diehr, the Court held that a
method claim that includes a physical transformation of matter is
patentable subject matter under 35 U.S.c. § 101.54 However, the Court
indicated that a method claim not involving a physical transformation of

35 U.S.C.A. § 271(b) (Westlaw 2007).
See Joy Techs., Inc. v. F1akt, Inc., 6 F.3d 770, 774 (Fed. Cir. 1993).
45
1d.
46 Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 1272 (Fed. Cir. 1986) (citing
Michalic v. Cleveland Tankers, Inc., 364 U.S. 325, 330 (1960)).
47 Kristin E. Gerdelman, supra note 42, at 200 I.
48
Water Techs. Corp., 850 F.2d at 660; Gerdelman, supra note 42, at 2000.
49 See Julie E. Cohen & Mark A. Lemley, Patent Scope and Innovation in the Software
Industry, 89 CAL. L. REv. I, 11-14 (2001).
50/d. at II.
43

44

51 A method claim and a process claim have the same meaning and are used interchangeably.
35 U.S.C.A. § 100(b) (Westlaw 2007).
52 Diamond v. Diehr, 450 U.S. 175, 192 (1980); Parker v. Flook, 437 U.S. 584, 590-94
(1978); Gottschalk v. Benson, 409 U.S. 63, 70-71 (1972).
53 Diehr, 450 U.S. at 192.
54 See id.
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matter may still be patentable. 55 The Court broadly stated that a method
claim is patentable subject matter if it "perform[ed] a function which the
patent laws were designed to protect.,,56 After the holding in Diehr, there
remained substantial uncertainty in defining patentable subject matter
under 35 U.S.c. § 101 for process claims that do not entail a physical
transformation of matter. 57
There were several cases in the 1980s and 1990s in which the
Federal Circuit and its predecessor, the United States Court of Customs
and Patent Appeals, struggled to apply the holding of Diehr to determine
whether software process claims should be patentable subject matter 35
U.s.c. § 101. 58 In an attempt to clarify the United States Supreme Court
holding in Diehr,59 the Federal Circuit in State Street Bank seemingly
eliminated the physical-transformation requirement. 60 The Federal
Circuit held that a method claim would be patentable subject matter so
long as it provided "a useful, concrete, and tangible result.,,61 The rule in
State Street Bank has arguably increased the scope of patentable subject
matter to include abstract ideas or mental thoughts. 62 As a result, since
State Street Bank, the United States Patent and Trademark Office has
issued an increasing number of software-method patents, especially
business-method patents. 63 The rapid increase in issued method patents
has generated harsh criticism of the rule developed in State Street Bank.64
C.

ISSUES FACING THE BIOTECH INDUSTRY UNDER THE CURRENT
INTERPRETATION OF 35 U.S.c. § 101
Similar to the computer software industry, the biotechnology

55
56

See id.
Id .

57 See Cathy E. Cretsinger, I. Intellectual Property: B. Patent: 4. Patentability: a) Computer
Software: AT&T Corp. v. Excel Communications, Inc., 15 BERKELEY TECH. LJ. 165, 168 (2000).
58 See In re Alappat, 33 F.3d 1526, 1542-44 (Fed. Cir. 1994); Arrhythmia Research Tech.,
Inc. v. Corazonix Corp., 958 F.2d 1053, 1056-60 (Fed. Cir. 1992); In re Meyer, 688 F.2d 789, 79496 (C.c.P.A. 1982); In re Abele, 684 F.2d 902, 907-908 (C.c.P.A. 1982).
59 Diehr, 450 U.S. at 192.
60 See State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir.
1998).
61 Id .
62 See Cretsinger, supra note 57 at 177-80.
63 Brief for Amicus Curiae Computer & Communications Industry Association in Support of
Petitioner at 14-15, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No.
04-067),
available
at
http://www.ccianet.org/modules/patentPDFs/CCIALabCorpMeritsAmicus[04-607J.pdf.
64 See Robert P. Merges, As Many as Six Impossible Patents Before Breakfast: Property
Rights for Business Concepts and Patent System Reform, 14 BERKELEY TECH. LJ. 577, 587 (1999).
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industry has experienced explosive growth and technological
advancement over the last thirty years. 65 One area of recent growth in
biotechnology has been in the medical diagnostic field, involving the
development of new blood tests (i.e., assays) for diagnosing a disease or
predicting the likelihood of developing a disease in the future. 66 For
example, such a test can measure a concentration of a particular chemical
or the presence of a genetic marker. 67
The medical diagnostics industry is very important to the United
States economy in regard to sales and the creation of jobs,68 and thus
significant benefits would flow from a clarification of 35 U.S.c. § 101.
The diagnostic portion of the biotech industry generated approximately
forty-six billion dollars in revenue and 187,500 jobs in the year 2004
alone. 69 The United States government has a significant interest in
tailoring patent law to provide an incentive for innovation, by promoting
commerce through the award of limited monopolies. 70 However, to
promote innovation through patents, the United States government must
exercise the right balance by granting a limited monopoly only when the
inventor provides the public a substantive advance in science and the
useful arts. 71
Broad-based method patents can be used to enjoin the performance
of diagnosing a disease.72 In essence, allowing a broad-based method

65 See John M. Golden, Biotechnology, Technology Policy, and Patentability: Natural
Products and Invention in the American System, 50 EMORY LJ. 101,113 (2001).
66 See Genetics: The Future of Medicine, NIH Publication No. 00-4873, at 9, available at
http://www.genome.govlPageslEducationKitlimageslnhgri.pdf (last visited Dec. 16,2006); Brief for
Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 21,
Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067); Brief for
Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of Petitioner at 12, Lab.
Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067) (noting
growth in genome analysis).
67 See Genetics: The Future of Medicine, NIH Publication No. 00-4873, at 9, available at
hnp:llwww.genome.govlPages/EducationKitlimageslnhgri.pdf (last visited Mar. 18,2007); Brief for
Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 1214, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)
(describing diagnostic tests for prostate cancer, AIDS, ovarian cancer, and neoplastic tissue).
68 Biotechnology Industry Organization (2005). Biotechnology Industry Facts; and Burrill
and Company (2005). Biotech 2006: What's Really Going to Happen. Gene Acres, Sept. 25,
available at http://www.cccbiotech.org/pdfltrainingneeds21stcentury.pdf.
69 Id.
70

71

See Bonito Boats v. Thunder Craft Boats, 489 U.S. 141,146 (1989).
See id.

72 See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of
Petitioner at 8-13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-067).
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claim amounts to granting a patent on the practice of medicine. 73
Examples of diseases covered by method claims are prostate cancer, 74
HIV/AIDS/5 breast cancer,76 ovarian cancer,77 and vitamin B
deficiency.78 In the practice of medicine, a physician will routinely order
a blood test to measure particular chemical or genetic information,
correlate the results to the presence or absence of a disease, and inform
the patient of the result. 79 Thus, the standard practice of medicine for
diagnosing a disease may be enjoined through broad-based method
patents.
Under one interpretation, the medical measurement step in
Metabolite Labs does not include a physical transformation of matter,
and thus it should not be patentable subject matter based on the U.S.
Supreme Court holding in Diehr. 80 However, the method-of-diagnosis
claim can be construed to provide a useful, concrete, and tangible result
and therefore could be patentable subject matter based on the Federal
Circuit holding in State Street Bank. 81 This inconsistency illustrates the
apparent dichotomy in standards for defining patentable subject matter
for process claims that has existed since the ruling in State Street Bank. 82

73 See Brief Amicus Curiae of AARP In Support of Petitioner at 17, Lab. Corp. of Am.
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
74 U.S. Patent No. 5,840,501 (issued Nov. 24, 1998) (quoted in Brief for Amicus Curiae
Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 12, Lab. Corp. of
Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)).
75 U.S. Patent No. RE38,352 (issued Dec. 16, 2003) (quoted in Brief for Amicus Curiae
Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 12, Lab. Corp. of
Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)).
76 U.S. Patent No. 5,709,999 (issued Jan. 20, 1998) (quoted in Brief for Amicus Curiae
Affymetrix, Inc. and Professor John H. Barton in Support of Petitioner at 19, Lab. Corp. of Am.
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
77 U.S. Patent No. 4,968,603 (issued Nov. 6, 1990) (quoted in Brief for Amicus Curiae
Perlegen Sciences, Inc. and Mohr, David Ventures in Support of Respondents at 13, Lab. Corp. of
Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)).
78 U.S. Patent No. 4,940,658 (issued July 10, 1990).
79 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1364 (Fed. Cir.
2004).
80 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921,
2927 (2006) (Breyer, J., dissenting).
81 See State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir.
1998).
82 Compare Diamond v. Diehr, 450 U.S. 175, 192 (1980) with State Street Bank, 149 F.3d at
1373.
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FACTS AND PROCEDURAL HISTORY OF LABCORP

1. Discovery of the Method
In Metabolite Labs, a trio of medical-school professors from the
University of Colorado and Columbia University discovered a method of
diagnosing a vitamin B deficiency.83 The discovered method involved a
correlation between the concentration of total homocysteine in blood and
a vitamin B deficiency. 84 The term "total homocysteine" represents the
aggregate concentration of four different forms of homocysteine. 85
Homocysteine is an amino acid that can be found in the human body. 86
Amino acids may be used to build proteins that exist in nature. 87
Vitamin B is an essential chemical necessary for the health and
development of humans. 88 Vitamin B complex is a group of vitamins
including BI (thiamin), B2 (riboflavin), B6 (pyridoxine), niacin,
pantothenic acid, folate, and BI2 (cobalamin).89 Although there are
several different vitamin B complexes, the specific type of vitamin B
deficiency referred to in this Note concerns only cobalamin (vitamin Bu)
and folate. Thus, all references to vitamin B hereinafter will refer only to
cobalamin and folate.
A vitamin B deficiency may cause one or more serious illnesses
including those that relate to cognitive dysfunction, birth defects, and
cancer. 90 If the vitamin B deficiency is detected early, a physician can
prescribe a vitamin supplement to improve the patient's health and
overcome the vitamin B deficiency.91 However, if the diagnosis is not
timely, a patient can suffer serious illness or death.92 Thus, although the
83 Brieffor Respondents at 1-2, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2006 VlL 303905.
84 Id. at 2.
For more information on homocysteine, see generally American Heart
Association, What is Homocysteine?, http://www.americanheart.org!presenter.jhtml?identifier=535
(last visited Sept. 16, 2006).
85 Brief for Respondents at 3, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905.
86 Brief for Petitioner at 2, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct.
2921 (2006) (No. 04-067), available at 2005 WL 3543099.
87 FuNDAMENTALS OF CLINICAL CHEMISTRY, 291 (Norbert W. Tietz ed., 3d ed. 1987).
88 Id. at 497.
89 1d. at 497-512, 815-18.
90 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358 (Fed. Cir.
2004).
91 1d .
92 See Brief for Respondents at I, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126
S. Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905.
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new method was initially repudiated by the medical community, it
provided physicians with a useful and previously unknown way of
detecting a vitamin B deficiency that eventually became well-accepted
and frequently referenced. 93
Traditionally, a vitamin B deficiency was initially diagnosed by
observing anemia and enlarged red blood cells in a patient's blood. 94
Mter the initial diagnosis, the deficiency was verified by measuring a
low concentration of vitamin B in the patient's blood. 95 Research studies
had demonstrated that a vitamin B deficiency was not detected in a
significant number of people using the traditional test. 96 Thus, a large
number of patients in need of immediate treatment were left untreated
because they were not diagnosed by the traditional test. 97
In contrast, the new total homocysteine test was much more
effective because of a much lower percentage of false negative results
(i.e., the proportion of patients with a vitamin B deficiency that were not
diagnosed).98 Therefore, the total homocysteine measurement was a
major breakthrough enabling the early diagnosis of a vitamin B
deficiency. Without the new test, millions of people with a vitamin B
deficiency would not be properly diagnosed, causing them to potentially
suffer a serious illness. 99
2. Licensing of the Idea
In addition to discovering the correlation between the total
homocysteine concentration and a deficiency in vitamin B, the medicalschool professors invented new and better assays for measuring total
homocysteine in blood. 100 Through their research, the universities that
employed the professors were able to obtain U.S. Patent No. 4,940,658
("'658 patent"). The '658 patent claimed a method of measuring the
total homocysteine concentration and a method of diagnosing a patient

93

Id. at 4-5.

Id. at 2. Anemia is a condition that consists of a relatively low concentration of red cells in
blood. FUNDAMENTALS OF CLINICAL CHEMISTR Y, 789 (Norbert W. Tietz ed., 3d ed. 1987).
95 Brief for Respondents at 2, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 s.
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905.
96 See id. at 4.
97
1d.
94

See id. at 2 n.2.
See id. at 4.
lOOMetabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358 (Fed. Cir.
2004). An assay is an analysis is to determine the presence, absence, or quantity of one or more
components. Merriam-Webster Online Dictionary, http://www.m-w.comldictionary/assay (last
visited Feb. 25, 2007).
98

99
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with a vitamin B deficiency. 101 Both Columbia University and the
University of Colorado assigned the patent to a predecessor of
Competitive Technologies, Inc. 102 In turn, Competitive Technologies
granted a patent license to Metabolite Laboratories, Inc. ("Metabolite
Labs"). 103 Metabolite Labs sublicensed the patent to Roche Biomedical
Laboratories to perform the total homocysteine assay.l04 Later, Roche
Biomedical Laboratories became Laboratory Corporation of America
("LabCorp,,).105
LabCorp performed the assay and paid royalties to both Metabolite
Labs and Competitive Technologies for six years.l06 In 1998, Abbott
Laboratories developed an improved total homocysteine assay. 107
LabCorp adopted the Abbott assay but did not pay royalties to
Metabolite Labs and Competitive Technologies when using the Abbott
assay. 108 However, LabCorp did continue to pay royalties when it used
the Metabolite Labs version. I09 LabCorp thought that royalty payments
were not necessary when using the Abbott version of the total
homocysteine assay.11O However, Metabolite Labs and Competitive
Technologies sued LabCorp for patent infringement and breach of
license because they asserted that the '658 patent covered any assay for
measuring total homocysteine, including the Abbott assay. II I

Metabolite Labs, 370 F.3d at 1358.
for Respondents at 6, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. Competitive Technologies is a
company that specializes in licensing technological developments to industry from universities. Id.
103 Brief for Respondents at 6, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. The University of Colorado
established Metabolite Labs so that the inventors could develop the total homocysteine assay into a
format available to physicians. Id.
104 Metabolite Labs, 370 F.3d at 1359.
105 Id .
106 Brief for Respondents at 7, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905. A physician would order the assay
and arrange to have the blood sample sent to LabCorp for performing the measurement of total
homocysteine. Id. at 7 n.3.
107 Brief for Respondents at 7, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905.
108 [d. at 8.
101

102 Brief

1(J9 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2923
(2006) (Breyer, J., dissenting).
110 See Brief for Respondents at 8, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126
S. Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905.
III Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358-59 (Fed. Cir.
2004).
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3. District Court Decision
At the district-court level, the jury found that LabCorp had infringed
the patent and breached the license agreement. 112 LabCorp was ordered
to pay nearly 3.7 million dollars in damages for breach of contract and 2
million dollars for willful infringement of the patent. 113
One of the main issues argued in the district court was whether
LabCorp infringed Claim 13 of the '658 patent. 114 Whether LabCorp
infringed rested on how the district court construed Claim 13: 15 Claim
13 describes "a method for detecting a deficiency of cobalamin or folate
in warm-blooded animals comprising the steps of: assaying a body fluid
for an elevated level of total homocysteine; and correlating an elevated
level of total homocysteine in said body fluid with a deficiency of
cobalamin or folate.,,1l6
During the Markman claim-construction hearing, I 17 LabCorp
wanted the court to construe "correlating" as establishing a mutual or
reciprocal relationship with "an elevated level of homocysteine." lIS
LabCorp also asserted that the correlating step must include a vitamin B
deficiency that causes either a hematologic or neuropsychotic
abnormality.119 The district court adopted only the initial portion of
LabCorp's construction, holding that "correlate" means "'to establish a
mutual or reciprocal relation of an elevated level of homocysteine," "but
declined to 'include a[ny] reference to [a] hematologic or neuropsychotic
abnormality.''' 120 The trial judge found that construing the correlation
step to include evidence of a hematologic or neuropsychotic disorder
would "impermissibly import[] a limitation from the specification" into
the claim. 121 LabCorp appealed to the Federal Circuit. 122
112 [d. Interestingly, Abbott Laboratories, who manufactured and sold the total homocysteine
assay kit used by LabCorp, was not charged with infringement in this suit. There are no facts
discussed in the case on whether Abbott Laboratories induced infringement.
113 Metabolite Labs, 370 F.3d at 1359.
114 [d. at 1361.
115 See id. at 1360.
116 U.S. Patent No. 4,940,658 (issued July 10, 1990) (emphasis added).
117 A Markman hearing is where the judge can construe the meaning of the language used in a
patent claim. See Markman v. Westview Instruments, Inc., 52 F.3d 967, 987 (Fed. Cir. 1995).
118 Metabolite Labs, 370 F.3d at 1361.
119 !d.

[d. (quoting LabCorp's Markman brief).
Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361 (Fed. Cir.
2004) (finding a hematologic or neuropsychotic disorder that is described in the written description
of the patent should not be required as a necessary result of the correlation step described in the
claim). A specification is a written description of the invention. 35 U.S.c. § 112 (Westlaw 2007).
122 Metabolite Labs, 370 F.3d at 1358.
120
121
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4. Federal Circuit's Affirmance of District Court
On appeal, LabCorp argued that the district court erred in
construing the term "correlating" too broadly.123 LabCorp argued again
that the term "correlating" should be limited to a vitamin B deficiency
that '''causes a hematologic or neuropsychiatric abnormality. ",124
However, the Federal Circuit affirmed the district court's construction. 125
The court then turned to the issue of direct infringement. 126 Based
on the district court's claim interpretation, the jury verdict had held
LabCorp liable for indirect infringement, but the jury also found that
physicians directly infringed the patent because they ordered the assay
and correlated the results. 127
As evidence to support the direct infringement, LabCorp's
Discipline Director testified at trial that physicians performed the
correlation step after receiving the results from LabCorp.128 As further
evidence that physicians performed this step, an inventor of the '658
patent "testified that it would be malpractice for a [physician] to receive
a total homocysteine assay without determining cobalamin/folate
deficiency." 129 The court noted that "'[c]ircumstantial evidence is not
only sufficient, but may also be more certain, satisfying and persuasive
than direct evidence. ",130 Therefore, the Federal Circuit found sufficient
evidence to support the jury finding that physicians directly infringed
because they would always be ethically compelled to think about the
correlation after ordering a total homocysteine assay.131
After physicians were established as direct infringers, the Federal
Circuit went on to analyze whether LabCorp had induced physicians to
infringe Claim 13. 132 LabCorp had published articles targeted to
physicians to inform them that elevated concentrations of total
homocysteine could be correlated to a vitamin B deficiency.133 In
addition, the articles stated that such a deficiency could be treated

See id. at 1361.
1d.
125 Id. at 1364.
126
ld .
127
1d.
128
1d.
129
1d.
123

124

130

1d. at 1365 (citing Moleculon Research Corp. v. CBS, Inc., 793 F.2d 1261, 1272 (Fed. Cir.

1986».
See Metabolite Labs, 370 F.3d at 1365.
1d.
133 1d.

131

132
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through vitamin supplements. 134 The Federal Circuit interpreted the
publications as evidence that LabCorp promoted the use of total
homocysteine assays for detecting a vitamin B deficiency.135 The
Federal Circuit therefore affIrmed the jury's finding that LabCorp had
induced infringement of Claim 13. 136
5. Denial of Certiorari by the United States Supreme Court

Mter losing on appeal, LabCorp filed a petition for a writ
ofcertiorari to the United States Supreme Court. 137 The Court initially
granted certiorari on only one issue: whether a method patent that directs
a party to simply correlate test results can validly "claim a monopoly
over a basic" scientific principle such that any physician necessarily
infringes the patent by merely thinking about the relationship after
looking at test results. 138 Although certiorari was initially granted, it was
subsequently dismissed as having been improvidently granted. 139
In dissenting from the dismissal of the petition for the writ of
certiorari, Justice Breyer acknowledged that there was a procedural
problem with the writ in that "LabCorp did not refer in the lower courts
to" an issue with 35 U.S.c. § 101. 140 Although the Court "might benefit
from the views of the Federal Circuit" 141 on the 35 U.S.c. § 101 issue,
Justice Breyer asserted that the Court nevertheless had the power to
adjudicate an issue that was not properly raised in the lower court, citing
United States v. Williams. 142
Because the issue was "fully briefed and argued by the parties, the
Government, and the [twenty] amici," he argued that the case could be
fairly adjudicated by the Supreme Court despite the absence of rulings by

135

[d.
[d.

136

[d.

134

137 Petition for a Writ of Certiorari, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126
S. Ct. 2921 (2006) (No. 04-067), available at 2004 WL 2505526.
138 [d.; Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 543
(2005) (limiting grant of certiorari to issue three only).
139 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (Lab Corp), 126 S. Ct. 2921, 2921
(2006).
140 Id. at 2925 (Breyer, J., dissenting).
141 [d. at 2925 (Breyer, J., dissenting) (citing United States v. Bestfoods, 524 U.S. 51, 72-73
(1998)).
142 [d. at 2925-26 (Breyer, J., dissenting) (citing United States v. Williams, 504 U.S. 36, 40
(1992)). The traditional rule is that the Supreme Court should not grant certiorari when the argument
was not pressed by the litigant or passed on by the court below. Williams, 504 U.S. at 41. The
Williams Court noted that the rule "operate[dj in the disjunctive, permitting review of an issue not
pressed so long as it has been passed upon." [d.
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the lower courts. 143 Justice Breyer conceded that it would have been
better for the issue to have been considered by the Federal Circuit, but
found "the extra time, cost, and uncertainty that further proceedings
would engender [were] not worth the potential benefit." 144
Justice Breyer emphasized that a timely clarification of 35 U.S.C §
101 was important because it would benefit medical researchers,
physicians, and the patients who depend on proper healthcare. 145 He
noted that the Federal Circuit's current interpretation for method-ofdiagnosis claims, such as Claim 13 of the '658 patent, "may inhibit
[physicians] from using their best medical judgment." 146 As a potentially
undesirable result of the Federal Circuit's interpretation, Justice Breyer
noted that physicians may be forced to spend time licensing patents and
searching for potentially infringing patents instead of focusing their
efforts on helping the public through the practice of medicine. 147
Additionally, Justice Breyer discussed whether Claim 13 was
patentable subject matter under 35 U.S.c. § 101. 148 He stated that "the
correlation between homocysteine· and vitamin deficiency set forth in
Claim 13 is a 'natural phenomenon.",149 As support, he noted that
Metabolite Labs had practically conceded that the correlation step
between total homocysteine and a deficiency in vitamin B standing alone
is a natural phenomenon. 150
Metabolite Labs, however, had asserted that Claim 13 was valid
because considered as a whole, it "entails a physical transformation of
matter" (the alteration of a blood sample) and "produces a useful,
concrete, and tangible result" (the diagnosis of a vitamin B
deficiency). 151 Justice Breyer rejected the first argument because Claim
13 does not describe an assay that transforms blood. 152 Claim 13 simply
describes the use of any assay for measuring total homocysteine, which
He
includes unpatented methods of measuring homocysteine. 153
interpreted Claim 13 to "instruct[] [a] user to (1) obtain test results and
143

LabCorp, 126 S. Ct. at 2926 (Breyer, J., dissenting).

144

[d.

145 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921,
2928 (2006) (Breyer, J., dissenting).

146

[d.

[d. at 2928-29.
[d. at 2927.
149 [d.
147

148

150 [d.
151 [d. (quoting Brief for Respondent at 33, 36, Lab. Corp. of Am. Holdings v. Metabolite
Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067)).
152 LabCorp, 126 S. Ct. at 2927 (Breyer, J., dissenting).
153

[d.
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(2) think about them.,,154 He rejected Metabolite Labs' argument as not
persuasive, because virtually any law of nature applied to "any useful
purpose could involve the use of empirical information obtained through
an unpatented means that might have involved transforming matter.,,155
Justice Breyer also rejected Metabolite Labs' second argument that
a process is patentable if it produces a "'useful, concrete, and tangible
result. '" 156 He noted that the Court itself had not held that all processes
that have a useful, concrete, and tangible result were patentable subject
matter, and "if taken literally [that] statement would cover instances
where [the] Court ha[d] held the contrary.,,157 Justice Breyer cited
several cases in which the Court had held process claims unpatentable,
even though they produced a useful, concrete, and tangible result. 158
Justice Breyer emphasized that he would reject Claim 13 as outside
the scope of patentable subject matter under 35 U.S.C. § 101, because it
"amount[ed] to a simple natural correlation, i.e., a 'natural
phenomenon. ",159 In this case, he interpreted the process claim as "an
instruction to read some numbers in light of medical knowledge." 160
Justice Breyer concluded that Claim 13 was unpatentable because the
correlation step was a "natural phenomenon" and there was nothing in
Claim 13 that "add[ed] anything more of significance." 161

154
155
156
157

[d.
[d.

[d. at 2928.
[d.

[d. (citations omitted). In 0 'Reilly v. Morse, the Court invalidated a process claim that
transmitted messages over long distances, which was certainly a useful, concrete, and tangible result.
See O'Reilly v. Morse, 56 U.s. 62, 112-13 (1854). In Flook, the Court invalidated a process claim
that triggered alarm limits for a catalytic converter, which was also a useful, concrete, and tangible
result. Parker v. Flook, 437 U.S. 584, 594 (1978). In Gottschalk, the Court invalidated a process
claim that converted decimal figures into binary figures, which would arguably be a useful, concrete,
and tangible result for improving the wiring system of a computer. Gottschalk v. Benson, 409 U.S.
63,73 (1972).
159 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2928
(2006) (Breyer, J., dissenting) (citing Flook, 437 U.S. at 588 n.9).
160 [d.
161 [d.
158
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ANALYSIS

A. THE METHOD IN CLAIM 13 Is NOT PATENTABLE UNDER UNITED
STATES SUPREME COURT PRECEDENT

1. Claim 13 Can Be Construed as a Mathematical Formula that Wholly
Preempts the Fieldfor Measuring Total Homocysteine
"[O]ne may not patent an idea.,,162 The United States Supreme
Court held in Gottschalk v. Benson that a process claim directed to a
mathematical formula would in effect be a patent on an idea if the
process claim wholly preempts the use of the mathematical formula. 163
In Gottschalk, the mathematical formula converted binary-coded decimal
numerals into pure binary numerals. l64 The alleged invention in
Gottschalk was that a binary number can be transformed into a different
state using a mathematical formula. 165 The claim was broadly drafted
such that all unknown and future uses of the mathematical formula
would infringe the patent. 166
The correlation step in Metabolite Labs is analogous to the
mathematical formula in Gottschalk. Claim 13 of the '658 patent may be
construed to have a mathematical formula in the correlation step.167 The
correlation step essentially consists of a physician comparing a total
homocysteine concentration to a threshold value. 168
If the total
homocysteine concentration is greater than the threshold, then the patient
is diagnosed with a vitamin B deficiency.169 The correlation step can be
translated to the following mathematical formula: if H > E, then there is a
vitamin B deficiency, where H = total homocysteine concentration, and E
= elevated level of total homocysteine. Construing the correlation step as
a mathematical formula does not change the meaning of the claim in any

Gottschalk, 409 U.S. at 71; accord Diamond v. Diehr, 450 U.S. 175, 185 (l980).
Gottschalk, 409 U.S. at 71-72.
164 Id. at 64
162
163

Id. Conversion of decimal numbers to binary numbers may be useful "within a computer's
wiring system." Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921,
2928 (2006) (Breyer, J., dissenting).
166 See Gottschalk, 409 U.S. at 68.
167 See In re Application of Richman, 563 F.2d 1026, 1030 (C.C.P.A. 1977) (noting that
words can essentially mean the same thing as a mathematical formula).
168 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1364, 1367
(Fed. Cir. 2004) (citing the '658 patent at col. 9, II 26-29).
169 See id.
165
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way, but it does illustrate the application to the holding in Gottschalk. 170
The mathematical formula is a compulsory step that is performed in
the physician's mind after ordering a total homocysteine assay, because
"it would be malpractice for a [physician] to receive a total homocysteine
assay without determining a vitamin B deficiency." 171 Therefore, a
physician necessarily uses the mathematical formula when ordering a
total homocysteine assay and infringes Claim 13. Conversely, the
mathematical formula cannot be used without performing an assay for
total homocysteine concentration because the concentration (i.e., H) is
part of the mathematical formula.
Accordingly, all uses of the
mathematical formula would infringe Claim 13 of the '658 patent. 172
Claim 13 of '658 patent should be invalidated because it wholly
preempts the use of the mathematical formula as defined here in the
correlation step, which violates the rule in Gottschalk. 173

2. The Mathematical Formula in Claim 13 Patents a Law of Nature
"[T]he discovery of a law of nature cannot be patented.,,174 The
United States Supreme Court, in Parker v. Flook, noted that "natural
phenomena ... are not the kind of 'discoveries'" that were meant to be
patented under 35 U.S.C. § 101.175 The Court defined a scientific
principle or a natural phenomenon to be a relationship that has always
existed even before its discovery.176 The Court used Newton's law of
gravity between two bodies as an example of a natural phenomenon that
has always existed, even before its discovery by Newton. 177 The Court
emphasized that mere recognition of an existing phenomenon does not

170
171

Gottschalk, 409 U.S. at 71-72.
Metabolite Labs, 370 F.3d at 1364.

172 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of
Petitioner at 11-12, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. CI. 2921 (2006)
(No. 04-067) ("[TJhe natural relationship between elevated amino acid levels and vitamin deficiency
has been 'pre-empted' by the patent claim."); Gottschalk, 409 U.S. at 71-72.
173 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of
Petitioner at 11-12, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. CI. 2921 (2006)
(No. 04-067); Gottschalk, 409 U.S. at 71-72. One may argue that Claim 13 does not have a
mathematical formula. However, to interpret the correlation step as being different from the
mathematical formula would allow a competent drafter to avoid the limitations of Gottschalk by
translating the mathematical formula into a series of steps in plain English. See In re Application of
Richman, 563 F.2d 1026, 1030 (C.C.P.A. 1977); Diamond v. Diehr, 450 U.S. 175, 192 (1980).
174 Parker v. Hook, 437 U.S. 584, 593 (1978).
175
1d.
176 1d . at 593 n.15.
177 Id. at 593.
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allow one to exclude others from its enjoyment. 178 The Court also
emphasized that "patentable subject matter must be new[] [and] not
merely heretofore unknown.,,179
The correlation of an elevated total homocysteine concentration
with a vitamin B deficiency is a law of nature. 180 The relationship
between total homocysteine and a· vitamin B deficiency has always
existed in human beings, long before LabCorp's important discovery)81
The process of regulating the production of homocysteine based on the
amount of vitamin B is part of a natural process in mammals. 182 Thus,
LabCorp should not have the right to exclude others from using the
natural phenomenon of an elevated total homocysteine concentration
correlating to a vitamin B deficiency merely because its patent assignors
were the first to discover such a relationship in nature. 183
3.

Claim 13 Does Not Entail a Physical Transformation of Matter
Necessary to Satisfy 35 U.S.c. § 101

The Court in Diehr held that if "a claim containing a mathematical
formula ... perform[s] a function which the patent laws were designed to
protect (e. g., transforming or reducing an article to a different state or
thing), then the claim satisfies the requirements of § 101.,,184 In Diehr,
the patentee claimed an improved process for molding rubber that used a
mathematical equation known as the Arrhenius equation. 185 The Court
found that the process claim comprised several steps for molding rubber
and thus did not wholly preempt all uses of the Arrhenius equation. 186
The Court found that the Arrhenius equation was applied as a tool
for improving the process of molding rubber. 187 The Court noted that the
claim described a complete and detailed step-by-step process "beginning
with the loading of a mold with raw, uncured rubber and ending with the

178

[d. (citing P. Rosenberg, Patent Law Fundamentals, § 4, p. 13 (1975)).

Flook, 437 U.S. at 593.
ISO See Brief for Petitioner at 21, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2005 WL 3543099.
181 See id.; Flook, 437 U.S. at 593.
182 See Brief for Petitioner at 21, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2005 WL 3543099.
183 See id.
179

184
185

Diamond v. Diehr, 450 U.S. 175, 192 (1980).
[d. at 177-179.

/d. at 187. The opinion suggests that the Arrhenius equation could still be used in the
process of curing rubber, but not in the same way as claimed by the patentee. [d.
186

187

Diehr, 450 U.S. at 177-178.
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eventual opening of the press at the conclusion of the cure.,,188 The
Court justified the patentability of the claim because the process was an
industrial process for physically producing an article that had historically
been eligible to receive patent protection. 189 Because the process claim
described the physical transformation of raw, uncured rubber to a
different state, the Court held that the claim satisfied the requirement of
35 V.S.c. § 101. 190
The Court accepted the petitioner's definition of a mathematical
formula, which is "a set of rules that leads [to] and assures development
of a desired output from a given input.,,191 In Diehr, the input was a
physical article, the raw, uncured rubber that goes into the mold, and the
output was a precision-molded rubber part.192 Analogously, for Claim
13, the input is the total homocysteine concentration, and the output is
the knowledge of whether there is a presence or absence of a vitamin B
deficiency. The total homocysteine concentration is a number and not a
physical article. 193 Therefore, Claim 13 does not have a transformation
or reduction of a physical article for satisfying 35 U.S.c. § 101 as
construed by Diehr.194
Metabolite Labs argued that Claim 13 does include a physical
transformation of homocysteine in blood and should therefore be
patentable subject matter based on Diehr. 195 Metabolite Labs supported
the argument by noting that the written description of the '658 patent
described a chemical process for transforming homocysteine into a
different state for enabling the measurement with an instrument. 196 The
chemical homocysteine may be construed as a physical article because it
is a tangible matter. 197 However, the express language of Claim 13 does
not include any limitations that describe a transformation of
homocysteine itself. 198 Claim 13 merely states "assaying a body fluid"
without stating any limitations for describing how to perform the

189

[d. at 184.
[d.

190

[d. at 184, 192-93.

188

See id.
See id. at 177.
193 Cf id. at 186 (discussing how the "alarm limit [was] simply a number" in Flook); see also
Parker v. Rook, 437 U.S. 584, 586 (1978).
194 Diehr, 450 U.S. at 192.
195 Brief for Respondent at 33-35, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126
S. Ct. 2921 (2006) (No. 04-067).
196 See id.
191

192

197

[d.

198 Brief for Petitioner at 27, Lab. Corp. of Am. Holdings v. Metabolite Labs .• Inc .• 126 S. Ct.
2921 (2006) (No. 04-067). available at 2005 WL 3543099.
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assay.l99 Because the Federal Circuit construed Claim 13 broadly to
include any method of measuring total homocysteine, the measuring step
should cover an assay that is either transformative or nontransformative. 2°O For there to be a finding that Claim 13 included a
transformation of blood, the claim must impermissibly read in a
limitation from the specification. 201 Therefore, Claim 13 should not be
construed to include a physical transformation of homocysteine, and thus
it cannot satisfy 35 U.S.c. § 101 based on the holding of Diehr. 202
4.

Claim 13 Does Not Contain a Process the Patent Laws Were
Designed to Protect

In a subsequent case, the Federal Circuit interpreted the use of
"e.g." in Diehr to mean that the process does not necessarily have to be a
transformation or reduction of an article to a different state or thing. 203
Thus, the court of appeals concluded that a method claim that does not
include a physical transformation can still be patentable under certain
circumstances. 204 In Diehr, the Court vaguely deemed a process to be
patentable if it is "performing a function which the patent laws were
designed to protect. ,,205 Because the transformation or reduction of a
physical article is absent in Claim 13, the process claim must next be
analyzed to determine whether it is a process that "patent laws were
designed to protect" for qualifying as statutory subject matter under 35
U.S.c. § 101.206
A method of detecting a disease, such as a vitamin B deficiency, is
the practice of medicine. 207 Patents that exclude physicians from
performing new and useful medical methods for treating sick patients,
independent of a particular type of instrument, have long been

199

!d.

200 If a future inventor were to discover a new method of measuring total homocysteine in
blood without adding reagent chemicals, Claim 13 would still cover the new measuring method. See
Brief for Petitioner at 27, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921
(2006) (No. 04-067), available at 2005 WL 3543099.
201 See Brief for Petitioner at 27, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2005 WL 3543099.
202 See Diamond v. Diehr, 450 U.S. 175, 192 (1980).
203 AT&T Corp. v. Excel Commc'ns, Inc., 172 F.3d 1352, 1358-59 (Fed. Cir. 1999).
204

[d.

Diehr, 450 U.S. at 192; Excel, 172 F.3d at 1358-59.
Excel, 172 F.3d at 1358-59.
2(J/ See Brief Amicus Curiae of AARP In Support of Petitioner at 9-10, Lab. Corp. of Am.
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
205

206
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controversia1. 208 In 1996, Congress enacted 35 U.S.c. § 287(c) to protect
physicians from being liable for patent infringement that occurs during
the performance of a medical activity.209 Thus, a physician who is a
direct infringer of a method-of-diagnosis patent would not be liable to
the patentee. 210 In such a situation, the patent law (Le., 35 U.S.c. §
287(c» was designed to protect the physician from liability for direct
infringement of the process claim. 211 Extrapolating Congress's reasoning
in enacting 35 U.S.C. § 287(c), a medical diagnostic claim would not be
a traditional type of claim that "patent laws were designed to protect.,,212

5.

Claim 13 Does Have a Useful, Tangible, and Concrete Result But
Still Does Not Satisfy 35 u.s.c. § 101

Metabolite Labs argued that the process in Claim 13 produced a
useful, tangible, and concrete result and should therefore be patentable
subject matter under 35 U.S.c. § 101.213 Metabolite Labs noted that
Claim 13 can be used to diagnose a person with a vitamin B deficiency,
making it possible to prevent a potentially dangerous medical
condition,214 the output of which is a useful, tangible, and concrete
result. 215
As noted above, in State Street Bank, the Federal Circuit held that a
process claim without a physical transformation of matter could still be
patentable subject matter so long as the result was useful, tangible, and
concrete. 216 However, a process claim still cannot be used to patent a
208

Morton v. N.Y. Eye Infinnary, 17 F. Cas. 879 (C.C.S.D.N.Y. I 862)DoNALD S. CHISUM, II CHISUM ON PATENTS § 1.03[3] (2007).
209 H.R. CONF. REp. No. 104-863, at 852-55 (1996); Brief Amicus Curiae of AARP In
Support of Petitioner at 9-10, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921
(2006) (No. 04-067); Todd Martin, Patentability of Methods of Medical Treatment: A Comparative
Study, 82 J. PAT. & TRADEMARK OFF. Soc'Y 381 (2000).
2\0 This assumes that a physician's order of an assay would constitute a "performance of a
medical ... procedure on a body" under 35 V.S.c. § 287(c). Brief Amicus Curiae of AARP In
Support of Petitioner at 9-10, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921
(2006) (No. 04-067). As a side note, 35 V.S.c. § 287(c) does not apply to LabCorp because the
'658 patent was filed on November 20, 1986, before the enactment of the statute. Id. at 9.
211 Brief Amicus Curiae of AARP In Support of Petitioner at 9-10, Lab. Corp. of Am.
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
212 See id.; Act of Sept. 30,1996, Pub. L. No. 104-208, 110 Stat. 3009-67-68.
213 Brief for Respondents at 36, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S.
Ct. 2921 (2006) (No. 04-067), available at 2006 WL 303905 (citing State Street Bank & Trust Co. v.
Signature Fin. Group, 149 F.3d 1368, 1373, 1375 (Fed. Cir. 1998)).
214
1d.
215
1d.
216 State Street Bank, 149 F.3d at 1373. Justice Breyer's dissenting opinion in LabCorp could
be interpreted as a hint that he and at least two other Justices would overrule State Street Bank.
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law of nature, according to the Court in Diehr. 217 Thus, assuming that
the Federal Circuit's holding in State Street Bank does not conflict with
the Supreme Court's holding in Diehr, a process claim can be patentable
if (1) the claim does not constitute an attempt to patent a law of nature
and (2) the process provides a useful, concrete, and tangible result. 218
However, as discussed above, Claim 13 of the '658 patent is a law
of nature. 219 Therefore, Claim'13 cannot be patentable subject matter
under 35 U.S.c. § 101, even though the process provides a useful,
tangible, and concrete result. 22o
B. THE FEDERAL CIRCUIT'S INTERPRETATION OF CLAIM 13's SCOPE
WAS

Too BROAD

In Metabolite Labs, the Federal Circuit broadly construed Claim 13
so that both physicians and the reference laboratory (i.e., LabCorp)
infringed. 221 The court affIrmed the jury's finding that LabCorp had
induced infringement and that physicians had directly infringed. 222 A
negative consequence of the Federal Circuit's holding is that a physician
can now directly infringe a patent while simply practicing medicine. 223
Further, a reference laboratory's publication that generally describes the
best practices in healthcare for detecting a deficiency in vitamin B can
now be construed as an inducement to infringe. 224

Justice Breyer noted that State Street Bank does say that "a process is patentable if it produces a
'useful, concrete, and tangible result.' But this Court has never made such a statement and, if taken
literally, the statement would cover instances where this Court has held the contrary." Lab. Corp. of
Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921, 2928 (2006) (Breyer, J.,
dissenting) .
217 Diamond v. Diehr, 450 U.S. 175, 185 (1980).
218 See State Street Bank, 149 F.3d at 1373; see also Diehr, 450 U.S. at 185.
219 See supra notes 174-183 and accompanying text.
220 See State Street Bank, 149 F.3d at 1373; see also Diehr, 450 U.S. at 185.
221 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361-65 (Fed. Cir.
2004).
222 [d. at 1364-65.
223 Brief for the American Medical Association, the American College of Medical Genetics,
the American College of Obstetricians and Gynecologists, the Association for Molecular Pathology,
the Association of American Medical Colleges, and the College of American Pathologists as Amici
Curiae in Support of Petitioner at 13-15, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126
S. Ct. 2921 (2006) (No. 04-067).
224 Brief of the American 'Clinical Laboratory Association as Amicus Curiae in Support of
Petitioner at 12-14, Lab. Corp. of Am. Holdings v. Metabolite Labs" Inc" 126 S. Ct. 2921 (2006)
(No. 04-067).
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Direct Infringement by Physicians

The Federal Circuit's holding that physicians directly infringed was
a surprising result. 225 Traditionally, direct infringement of a method
claim requires that a single entity perform all of the steps. 226 Thus, a
physician would have to perform the assaying step and the correlating
step to support a finding of direct infringement. 227
Technically,
physicians did not perform the assay step, which should have prevented a
finding of direct infringement. 228 The assaying step was performed at
LabCorp, where the blood sample was mixed with reagent chemicals and
processed with a laboratory instrument to obtain a total homocysteine
concentration. 229
The Federal Circuit inexplicably broadened the assaying step to also
include the ordering of an assay by a physician. 23o Based on the plain
language of Claim 13, the Federal Circuit has therefore appeared to
establish an agency relationship between the physician and LabCorp to
find that the physician effectively peiformed the assaying step.231 This
was not altogether unprecedented. Some courts have held that direct
infringement can be found when an independent contractor or agent is
used to perform at least one of the steps of a method patent for
manufacturing an article. 232 More recently, some courts have loosened
the rule for direct infringement so long as there is "some connection"
between the two parties performing the method claim. 233
The Federal Circuit found that physicians performed the correlation

225
226

See DONALD S. CHISUM, 5-16 CHISUM ON PATENTS sUPP. to § 16.02[6][a] (2007).
See Mark A. Lemley, Inducing Patent Infringement, 39 V.c. DAVIS L. REV. 225, 226

(2005).
227

See id.

228 See Mobil Oil Corp. v. Filtrol Corp., 501 F.2d 282,291-92 (9th Cir. 1974) (noting that it
was questionable "whether a method claim can be infringed when two separate entities perform
different operations and neither has control of the other's activities"); CHISUM, supra note 208, §
16.02[6][a] ( "A thorny problem arises when different persons successfully perform the steps of a
patented process.").
229 See Brief for Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support
of Respondents at 8, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-067).
230 Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1364 (Fed. Cir.
2004).
231 See CHISUM, supra note 225.
232 E.g., Crowell v. Baker Oil Tools, Inc., 143 F.2d 1003, 1004 (9th Cir. 1944).
233 Faroudja Labs., Inc. v. Dwin Electronics, Inc., No. 97-20010 SW, 1999 WL 111788, at *5
(N.D. Cal. Feb. 24,1999) (citations omitted); E.I. DuPont De Nemours & Co. v. Monsanto Co., 903
F. Supp. 680, 735 (D. DeI.l995), affd, 92 F.3d 1208 (Fed. Cir. 1996).
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step, based on indirect evidence. 234 For this case, direct evidence would
probably not be available unless physicians admitted to performing the
correlation step in their minds. As one inventor testified, "[I]t would be
malpractice for a [physician] to receive a total homocysteine assay
without determining a [vitamin B] deficiency.'.z35 The court found that
this supported the theory that physicians had performed the correlation
step when merely ordering an assay.236
Thus, a physician must now elect either to perform the mental step
of correlating a total homocysteine concentration with a vitamin B
deficiency or to commit malpractice. This leads to the absurd outcome
that a physician should have an irresistible impulse to think about a
vitamin B deficiency every time a total homocysteine assay is ordered
and therefore infringe Claim 13 of the '658 patent. Using this logic, the
mere ordering of a total homocysteine test by a physician will necessarily
result in a direct infringement. 237 Even if a physician intends to correlate
the total homocysteine concentration with a cardiac disease, the
physician must additionally perform a correlation to a vitamin B
deficiency too, and therefore infringe the Claim 13 of the '658 patent. 238
Therefore, based on the broad construction, a physician cannot avoid
performing the correlation step and thus infringes Claim 13 of the '658
patent when ordering a total homocysteine assay for the purpose of
diagnosing a cardiac disease. 239
In summary, based on the holding of Metabolite Labs, physicians
can directly infringe a method-of-diagnosis claim by merely ordering an
assay and thinking about it. 240 Such a broad interpretation will inhibit
both the practice of medicine and research into new or improved medical
assays.241 Therefore, the rate of innovation in discovering new and better
medical assays will likely decrease because of the increased possibility
of patent infringement based on the holding of Metabolite Labs.

234

Metabolite Labs, 370 F.3d at 1364-65.

235

[d. at 1364.

236

See id.

237 Brief for Petitioner at 29, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct.
2921 (2006) (No. 04-067), available at 2005 WL 3543099.
238 [d. at 26; see Brief of the American Heart Association as Amicus Curiae in Support of
Petitioner at 24, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No.
04-067). It should be noted that there is strong interest in using the total homocysteine assay for
diagnosing and treating cardiovascular disease. [d. at 18-19.
239 See Brief of the American Heart Association as Amicus Curiae in Support of Petitioner at
24, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
240 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921,
2927 (2006) (Breyer, J., dissenting).
241 See id. at 2922.
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LabCorp's Liability for Inducement to Infringe

The Federal Circuit affirmed the jury's finding that LabCorp
induced infringement because of its published article, which taught that
elevated concentrations of total homocysteine can be correlated to a
deficiency of vitamin B.242 In other words, LabCorp was found liable for
infringement by publishing sound medical advice for helping patients
and saving their lives. 243 LabCorp had merely published information
regarding the diagnosis and treatment of a vitamin B deficiency,244 which
was already published in a medical journat245 and in a patent
specification. 246 With the Federal Circuit's decision, the '658 patent
essentially enjoins people from communicating information needed to
enable better medical treatment. 247
Under the Federal Circuit's reasoning, anyone, not just a medical
reference laboratory like LabCorp, who publishes information stating the
relationship between total homocysteine and a deficiency of vitamin B
may be found liable for inducement to infringe Claim 13. Such a broad
reading of medical diagnostic patents could have a chilling effect on free
speech in terms of communicating good medical advice or the practice of
medicine. 248 In general, a decrease in the free exchange of information
will also have an effect on innovation in the area of developing new and
improved medical assays.z49 Free communication of ideas generally
promotes research and the development of inventions. 25o "[T]he ultimate
goal of the patent system is to bring new designs and technologies into
242

See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1365 (Fed. Cir.

2004).
243 See Brief Amicus Curiae of AARP In Support of Petitioner at 12-14, Lab. Corp. of Am.
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
244 See Metabolite Labs, 370 F.3d at 1365.
245 John Lindenbaum, M.D., Edward B. Healton, M.D., David G. Savage, M.D., John C.M.
Brust, M.D., Thomas J. Garrett, M.D., Elaine R. Podell, B.A., Paul D. Marcell, B.S., Sally P.
Stabler, M.D., & Robert H. Allen, M.D., Neuropsychiatric Disorders Caused by Cobalamin
Deficiency in the Absence of Anemia or Macrocytosis, 318 NEW ENGLAND JOURNAL OF MEDICINE
1720-28 (June 30, 1988), available at 2005 WL 3939546, at *211.
246 U.S. Patent No. 4,940,658 (issued July 10, 1990).
247 See Brief Amicus Curiae of AARP In Support of Petitioner at 12-14, Lab. Corp. of Am.
Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-067).
248 Cf Washington Legal Found. v. Henney, 202 F.3d 331, 335-336 (D.C. Cir. 2000) (noting
that a First Amendment right existed to provide published articles to physicians about a drug's
benefits without violating the Food and Drug Administration Modernization Act (FDAMA». Later,
the FDA asserted that an amended version of the FDAMA did not prohibit the dissemination of
published articles causing the constitutional issue to be moot. ld. at 334.
249 See W. Fritz Fasse, The Muddy Metaphysics of Joint lnventorship: Cleaning Up After the
1984 Amendments to 35 U.S.c. § 116,5 HARV. J. LAW & TECH. 153, 159-60 & n.37 (1992).
250 See id.
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the public domain through [publication].,,251
Medical researchers must now be careful about their research
activities and their publications. Based on Madey v. Duke University,
even academic researchers can be liable for infringement of patents when
performing basic research with a potential profit motive.252 Any
publication that can be construed as sound medical advice in diagnosing
a disease can now be potentially used as a basis for inducement to
infringe a patent. 253 In view of Metabolite Labs, a patent can be a prior
restraint that inhibits publication of scientific information. Moving
forward, a researcher will now have to contemplate searching prior
patents before publishing because the researcher could potentially be
liable for inducement to infringe if the publication happens to teach a
process that infringes a patent. 254
Ironically, LabCorp would likely have been better off not publishing
the article and waiting for physicians to learn about the beneficial use of
the assay through other means. For example, an academic researcher or
a medical professional society255 could have published the benefits of the
'658 patent to educate physicians about total homocysteine
measurements causing physicians to order the assay from LabCorp.
Based on the holding of Warner-Lambert v. Apotex, LabCorp's mere
knowledge alone that physicians would likely infringe the '658 patent
was not enough for a finding of inducement to infringe. 256 . Therefore,
LabCorp could have avoided an inducement to infringe by not publishing
the article and simply selling the assay to physicians who learned about
the benefits through other means.257

251 Bonito Boats v. Thunder Craft Boats, 489 U.S. 141, 151 (1989).
252 Madey v. Duke Univ., 307 F.3d 1351, 1362 & n.7 (Fed. Cir. 2002) ("[Nlon-profit status of
the user is not determinative" for determining if experimental use exception applies because nonprofit institutions can have "an aggressive patent licensing program from which it derives a not
insubstantial revenue stream").
253 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1365 (Fed. Cir.
2004).
254 See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (LabCorp), 126 S. Ct. 2921,
2928-29 (2006) (Breyer, J., dissenting).
255 Examples of medical professional societies are the American Medical Association,
American Association of Clinical Chemistry, and American Heart Association.
256Wamer-Lambert Co. v. Apotex Corp., 316 F.3d 1348, 1363 (Fed. Cir. 2003) (citing
Manville Sales Corp. v. Paramount Sys., Inc., 917 F.2d 544, 553 (Fed.Cir.1990)). Apotex sought to
market a generic drug that could be used to infringe a new method-of-use patent owned by WamerLambert. [d. at 1352. However, the Federal Circuit found no inducement to infringe by Apotex
because it did not seek to market the drug for the patented use. See id. at 1365. The fact that Apotex
probably knew that the majority of the generic drug sales would be used for the infringing use was
not enough to establish liability. [d.
257 See Warner-Lambert, 316 F.3d at 1363.
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C. PUBLIC POLICY CONSIDERATIONS

1. Claim 13 Stifles Future Development

In the past, the United States Supreme Court has used public policy
to invalidate a broad patent claim that essentially preempts the field. 258 It
is instructive to examine an early patent law case. Samuel Morse, who
invented the telegraph, had obtained a broad claim directed to any
method of using electromagnetism, independent of his device, for
transmitting messages over any distance. 259 The Court found that the
broad claim would preempt any use of the natural phenomenon known as
electromagnetism for transmitting messages. 260 Because the claim gave
an exclusive right to every improvement in which electromagnetism was
used for transmitting a message, the Court invalidated this claim as being
too broad. 261
The Court noted that allowing Morse's broad claim would inhibit
improvements in the field of using electromagnetism for transmitting
messages and that the public would be deprived of the potential
benefit. 262 The Court speculated that a future inventor might invent an
improved method for transmitting messages using electromagnetism
without using any part of the process or combination set forth in the
Morse patent. 263 According to the Court, such improvements could be an
improved machine that is less complicated, more robust, less expensive
to build, and less expensive to operate. 264 The Court wanted to prevent
Morse from having patent rights to all future improvements if he did not
contribute to them. 265 The Court noted that allowing Morse's broad
claim would prevent a future inventor from using the improved machine
unless Morse provided his permission. 266 In summary, the Court held
Morse's broad generic claim invalid so that the public could benefit from
improvements by entities other than Morse. 267
Morse's claim covering any use of electromagnetism is analogous

See O'Reilly v. Morse, 56 U.S. 62, 113 (1854).
See id. at 112.
260 Id. at 112-113.
261 Id. at 1l3.
262
1d.
263
1d.
258

259

264

Id.

CHISUM, supra note 208, § 1.03[2][c]; see Morse, 56 U.S. at 113.
56 U.S. at 113.
267
1d.

265

266 Morse,
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to Metabolite's claim covering any method of measuring total
·268
The use 0 f l
.
f or transffilttmg
..
e ectromagnetlsm
a
homocysteme.
message necessarily included a step for measuring electromagnetism. 269
Additionally, Claim 13 covers unpatented methods and future methods
for measuring total homocysteine concentration that is analogous to
Morse's broad claim that preempted the use of electromagnetism. 270
Thus, Claim 13 would cover every improvement to the method of
measuring total homocysteine even if Metabolite Labs does not
contribute to the improvements, which is exactly the same situation that
. d'morse.
M
271
eXlste
The '658 patent has already prevented the public from benefiting
from improvements to the total homocysteine assay. Not surprisingly,
one inventor did improve the method of measuring total homocysteine
after the original discovery cited in the '658 patent. 272 Abbott
Laboratories commercialized an improved assay, which required only a
few minutes as opposed to upwards of eighteen hours with the
Metabolite method. 273 Additionally, the Abbott assay was less laborintensive and therefore less expensive than the Metabolite assay.274 The
public could potentially benefit from the Abbott assay in the form of
reduced assay cost and a reduced turnaround time.275 However, the
jury's finding that a physician's use of Abbott's improved assay
infringed Claim 13 was upheld by the Federal Circuit. 276 Thus,
Metabolite Labs can block the use of the improved assay even though it
did not contribute to the improvement. In summary, Claim 13 should be
invalidated based on the public policy reasons described in Morse;
otherwise the public cannot benefit from improvements to the assay.277

268 Compare Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358-59
(Fed. Cir. 2004) with Morse, 56 U.S. at 112.
269
See Morse, 56 U.S. at 112-13. The measurement step occurred when the armature moved
in response to the presence or absence of a sufficient amount of electromagnetism to form a dot or a
dash.
270 Compare Metabolite Labs, 370 F.3d at 1358-59, with Morse, 56 U.S. at 112.
271 Morse, 56 U.S. at 112-13.
272 Brief for Petitioner at 9, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct.
2921 (2006) (No. 04-067), available at 2005 WL 3543099.
273 [d.
274 [d.
275 In general, a short test time has a big advantage because a physician can communicate the
results to the patient faster. Additionally, the physician can start treatment for the vitamin B
deficiency much sooner.
276 See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1365 (Fed. Cir.
2004).
m See O'Reilly v. Morse, 56 U.S. 62,112-13 (1854).
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2. Broad Method Claims Will Inhibit Future Research Needed by the
Public-An Example Is a Genetic Test for Breast Cancer
There is a great need to develop new and improved medical assays
to help identify diseases and to provide better treatment options to the
patient. 278 In particular, there has been an explosion in research activity
for genetic tests. 279 New and better genetic tests may allow earlier and
more accurate diagnosis of diseases, better prediction of whether a
patient will be diagnosed with a particular disease in the future,
personalized drugs that are adapted for maximal efficacy based on a
person's genetic sequence, and faster development cycles for drug
development. 280 Allowing broad diagnostic claims, as did the court of
appeals in Metabolite Labs,281 will have a chilling effect on the
development of better laboratory assays.282 The following illustrates the
chilling effect on future research by describing an example of a genetic
test that has a need for improvement but is limited because of broad
method claims.
Myriad Genetics offers a genetic test that predicts whether a person
has a strong likelihood of getting breast cancer. 283 If a person has a
mutated BRCAI or BRCA2 gene, then the person has a thirty-six to
eighty-five percent chance of getting breast cancer?84 In comparison,
about thirteen percent of the general population will be diagnosed with
breast cancer. 285 The discovery of a gene that predicts an increased
likelihood of getting breast cancer was a pioneering breakthrough. 286
From the patient's viewpoint, however, the BRCAI and BRCA2 test

278 See Brief of the American Clinical Laboratory Association as Amicus Curiae in Support of
Petitioner at 8-13, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-067).
279 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of
Petitioner at 15-20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-067).
280 See id.
281 Metabolite Labs, 370 F.3d at 1363-64.
282 See Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of
Petitioner at 20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No.
04-067).
283 Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the Balance
Among Competing Interests, 50 CLEV. ST. L. REv. 253, 269 (2002).
284 National Cancer Institute: U.S. National Institute of Health, Genetic Testing for BRCAI
and BRCA2, http://www.nci.nih.gov/cancertopics/factsheetlRiskIBRCA (last visited Sept. 25,2006).
285 Id .
286 See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCIENCE 698, 699 (1998).
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may cause more confusion than it is worth. 287 For instance, even if the
mutation is detected, there is up to a sixty-four percent chance that the
patient will not get breast cancer. 288 In other words, a patient who was
diagnosed as having the BRCAI or BRCA2 gene will have to deal with
the stress of possibly getting breast cancer for the rest of his or her ·life,
even though there is still a significant chance (up to sixty-four percent)
that breast cancer will not occur.289
A person who has a mutated BRCAl or BRCA2 gene will struggle
with whether to take preemptive action to improve his or her outcome. 290
Although the person may be a prime candidate for considering an
experimental drug 291 or procedure292 to prevent the onset of breast
cancer, there will be a risk of serious side effects. 293 To further
complicate matters, as many as sixty-four out of a hundred people with
the gene mutation will not get the disease and will thus be treated
unnecessarily.294 Therefore, although the BRCAI and BRCA2 test for
breast cancer shows great promise, there is a clear need to improve the
test's predictive power. 295
For entities other than Myriad Genetics, there is little incentive to
develop a better multiple gene test that uses BRCAI or BRCA2, because
such a test will infringe one of Myriad Genetics' patents. 296 Myriad
287 See David E. Adelman, A Fallacy of the Commons in Biotech Patent Policy, 20 BERKELEY
TECH. L.J. 985, 1005-06 (2005).
288 National Cancer Institute: U.S. National Institute of Health, Genetic Testing for BRCAI
and BRCA2, http://www.nci.nih.gov/cancertopics/factsheetiRiskIBRCA (last visited Sept. 25,2006).
289
Id .
290 See id.

291 An example of an experimental drug for preventing breast cancer is tamoxifen. National
Cancer Institute: U.S. National Institute of Health, Genetic Testing for BRCAI and BRCA2,
http://www.nci.nih.gov/cancertopicslfactsheetiRiskIBRCA (last visited Sept. 25,2006).
292 As an extreme example of an experimental procedure, some women with the gene
mutation have elected to remove their breast tissue (i.e., mastectomy) to prevent the possible
occurrence of breast cancer. National Cancer Institute: U.S. National Institute of Health, Genetic
Testing for BRCAI and BRCA2, http://www.nci.nih.gov/cancertopicslfactsheetlRiskIBRCA (last
visited Sept. 25, 2006).
293 An example of an experimental drug that caused serious side-effects was Prempro
(hormone
replacement
therapy).
Biospace.com,
http://www.biospace.com!news_story.aspx?StoryID=8486 (last visited Dec. 31,2006). A large scale
NIH study showed that Prempro actually increased the risk of breast cancer as well as the risk of
other diseases such as heart disease, stroke, and dementia. Id. Unfortunately, a significant number
of women used Prempro and, in the process, helped Wyeth generate about one billion dollars in sales
for the year 200 I. Id.
294 National Cancer ,Institute: U.S. National Institute of Health, Genetic Testing for BRCAI
and BRCA2, http://www.nci.nih.gov/cancertopics/factsheetiRiskIBRCA (last visited Sept. 25,2006).
295 See David E. Adelman, A Fallacy of the Commons.in Biotech Patent Policy, 20 BERKELEY
TECH. LJ. 985,1005-06 (2005).
296 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the
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Genetics has a broad method claim that essentially patents a law of
nature similar to Claim 13 of the '658 patent. 297 Any improved test that
uses BRCAI or BRCA2 will require a license from Myriad Genetics. 298
Assuming that Myriad Genetics would grant a reasonable license,299 the
researcher would then be burdened with increased costs for developing
the improved assay or risk being sued for patent infringement. 300
Because research is a high-risk and costly investment, researchers will
tend to avoid developing better assays that require a licensing agreement
and look to develop new assays that are unencumbered by existing
patents. 30 1
Discovering a better breast-cancer-prediction assay in an expedited
manner that uses multiple genes 302 including either BRCA1, BRCA2, or
a combination thereof is a very complicated problem that would likely
require a large-scale effort using the world's best and brightest

Balance Among Competing Interests, 50 CLEV. ST. L. REV. 253,264-267 (2002).
297 Compare U.S. Patent No. 4,940,658 (issued July 10, 1990) (correlating an elevated level
of total homocysteine with diagnosing a vitamin B deficiency) with U.S. Patent No. 5,709,999
(issued Jan. 20, 1998) (correlating the presence of a particular gene mutation with the likelihood of
developing breast cancer); Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in
Support of Petitioner at 18-20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct.
2921 (2006) (No. 04-067).
298 See Jordan Paradise, European Opposition to Exclusive Control Over Predictive Breast
Cancer Testing and the Inherent Implications for u.s. Patent lAw and Public Policy: A Case Study
of the Myriad Genetics' BRCA Patent Controversy, 59 FOOD & DRUG LJ. 133, 149 (2004).
299 Myriad Genetics has not granted an exclusive license to anyone for the breast cancer
patents. Shan shan Zhang, Comment, High Tech lAw Institute Publications: Proposing Resolutions
to the Insufficient Gene Patent System, 20 SANTA CLARA COMPUTER & HIGH TECH. L.J. 1139, 1159
(2004).
300 See Jordan Paradise, European Opposition to Exclusive Control Over Predictive Breast
Cancer Testing and the Inherent Implications for u.s. Patent lAw and Public Policy: A Case Study
of the Myriad Genetics' BRCA Patent Controversy, 59 FOOD & DRUG LJ. 133,149-50 (2004). The
risk of being sued for patent infringement appears to be significant. Mildred K. Cho et aI., Effects of
Patents and licenses on the Provision of Clinical Genetic Testing Services, Journal of Molecular
Diagnostics, 25 JOURNAL OF MOLECULAR DIAGNOSTICS 3, 5 (2003), available at
http://www.bioethics.upenn.edu/proglethicsgeneslpdflcho_etal_2003.pdf. A survey of laboratories
performing genetic tests showed that sixty-five percent of the laboratories have been contacted by a
patent holder regarding potential infringement. Id. In addition, about fifty percent of the survey
participants decided not to develop or perform a genetic test specifically because of intellectualproperty considerations. Id. at 7.
301 See Jordan Paradise, European Opposition to Exclusive Control Over Predictive Breast
Cancer Testing and the Inherent Implications for u.s. Patent lAw and Public Policy: A Case Study
of the Myriad Genetics' BRCA Patent Controversy, 59 FOOD & DRUG LJ. 133, 149-150 (2004).
302 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the
Balance Among Competing Interests, 50 CLEV. ST. L. REV. 253, 272-273 (2002). One logical
possibility for improving the test's predictive power is to discover one or more genes that can be
combined with either the BRCAI or BRCA2 gene. Id. The theory is that two genes (or more) are
better than one for predicting a complicated disease such as breast cancer. See id.
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researchers. 303 Because Myriad Genetics is only one company, it does
not have sufficient resources to try all possible combinations of genes
and strategies to improve the assay. As a result, Myriad Genetics may
have an underutilized monopoly on a natural phenomenon that is an
important piece for solving the breast-cancer-prediction puzzle. 304 Thus,
Myriad Genetics is likely slowing down the progress of improving the
assay because of its broad patent position. 305
Myriad Genetics may have little financial incentive to incrementally
improve its assay for breast cancer. Because Myriad Genetics can charge
a relatively high fee for its test,306 it may not want to bother taking on the
financial risk to incrementally improve its technology. Thus, Myriad
Genetics may be able to make more money by simply selling the BRCAI
and BRCA2 test until its patents expire, because of its broad patent
pOSItion. To further complicate matters, Myriad Genetics may not be
able to recoup its investment costs through increased sales by improving
its test, because the current test may be too profitable. 307
In summary, there is a need to incrementally improve diagnostic
assays such as the BRCAI and BRCA2 test, but allowing patents with
broad method claims will inhibit such improvements. 308 With the breastcancer test, for example, more reliable laboratory tests will enable better
treatments or at least enable more rational decisions about electing
experimental treatments. 309 The public has a need for better laboratory

303 See David E. Adelman,
A Fallacy of the Commons in Biotech Patent Policy, 20
BERKELEY TECH. L.l. 985, 1006-1024 (2005). "[TJhe dichotomy between genetic-data production
and invention creates an environment in which research opportunities are, as a practical matter,
unbounded because they far exceed the capacities of the scientific community." Id. at 1017.
3()4 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the
Balance Among Competing Interests, 50 CLEV. ST. L. REv. 253,270 (2002).
305 See id. at 266. This situation has been referred to as a "tragedy of the anticommons,"
where a resource is underused "because too many people are excluded from using the resource," as
is the case when a natural phenomenon is patented. See id.
306 See Shanshan Zhang, Comment,
High Tech Law Institute Publications: Proposing
Resolutions to the Insufficient Gene Patent System, 20 SANTA CLARA COMPUTER & HIGH TECH. L.l.
1139, 1159 (2004). Myriad Genetics charges about $2700 per test that is performed exclusively at
Myriad Genetics' laboratory in Utah. Id. at 1159-60. Therefore, all blood samples from around the
world must be sent to only one laboratory in Utah to have a BRCAI or BRCA2 test performed. Id.
307 See Shanshan Zhang, Comment,
High Tech Law Institute Publications: Proposing
Resolutions to the Insufficient Gene Patent System, 20 SANTA CLARA COMPUTER & HIGH TECH. L.J.
1139, 1159 (2004).
308 Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the Balance
Among Competing Interests, 50 CLEv. ST. L. REv. 253,268 (2002).
309 See National Cancer Institute:
U.S. National Institute of Health, Genetic Testing for
BRCAI and BRCA2, http://www.nci.nih.gov/cancertopicslfactsheetlRisklBRCA (last visited Sept.
25,2006).
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tests that can be used as a tool for improving healthcare. 3lo There is a
large number of diseases that could be potentially diagnosed and treated
more effectively through improved diagnostic testing, such as
Alzheimer's disease, rheumatoid arthritis, cardiovascular disease,
diabetes, osteoporosis, schizophrenia, and autism. 311
However,
researchers will not have an incentive to take on the risk of incrementally
improving an assay if broad diagnostic claims are allowed to remain
valid, even when there is a market-driven, unmet need for such an
improvement. 312

III. CONCLUSION
The United States Supreme Court should have reversed the Federal
Circuit's holding in Metabolite Labs. 313 The method-of-diagnosis claim
in Metabolite Labs is the equivalent of a mathematical formula that
wholly preempts a law of nature. 314 Further, the method-of-diagnosis
claim in Metabolite Labs does not entail a physical transformation of
matter to satisfy 35 U.s.c. § 101 based on Diehr. 315 Claim 13 of the
'658 patent does provide a useful, tangible, and concrete result for
diagnosing a medical disease, satisfying the requirements of State Street
Bank,316 but it still does not satisfy 35 U.S.c. § 101, because Claim 13 is
an attempt to patent a law of nature. The Federal Circuit affIrmed a
construction of the method-of-diagnosis claim that is so broad that
improvements to medical assays and healthcare will now be stifled. 317

310 Brief for Amicus Curiae Affymetrix, Inc. and Professor John H. Barton in Support of
Petitioner at 12-20, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-067).
311 Brief for Amicus Curiae Perlegen Sciences, Inc. and Mohr, David Ventures in Support of
Respondents at 21, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-067).
312 See Melissa E. Horn, Note, DNA Patenting and Access to Healthcare: Achieving the
Balance Among Competing Interests, 50 CLEV. ST. L. REV. 253,269 (2002).
313 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc. (Lab Corp) , 126 S. Ct. 2921 (2006);
Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354 (Fed. Cir. 2004).
314 See supra notes 174-183 and accompanying text.
315 LabCorp, 126 S. Ct. at 2927 (Breyer, J., dissenting); Diamond v. Diehr, 450 U.S. 175, 192
(1980).
316 State Street Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1373 (Fed. Cir.
1998).
317 Metabolite Labs, 370 F.3d at 1358.
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